Hormone therapy - Weighing up the evidence

Australian Family Physician

Volumn 33, Issue 11, 2004, Pages 875-880

  Teede, Helena J ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; BREAST TUMOR; CARDIOVASCULAR DISEASE; DEMENTIA; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; FRACTURE; HUMAN; MENOPAUSE; MIDDLE AGED; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK FACTOR; STATISTICS; THROMBOSIS;

AGED; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; DEMENTIA; ESTROGEN REPLACEMENT THERAPY; FEMALE; FRACTURES, BONE; HUMANS; MENOPAUSE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS; THROMBOSIS;

EID: 16644376883     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes. Cochrane Database of Systematic Reviews. 2, 2004.
2. Naftolin F, Taylor HS, Karas R, et al. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fert Steril 2004;816:1498-1501.
3. Teede H. Hormone replacement therapy and the effects on cardiovascular and cerebrovascular disease. Best Pract Clin Endocrinol Metab 2003;171:73-90.
4. Hulley S, Grady D, Bush T, et al. HERS Research Group. Randomised trial of oestrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1998;2807:605-613.
5. Grady D, Herrington D, Bittner V, et al. HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Oestrogen/Progestin Replacement Study follow up (HERS II). JAMA 2002;2881:49-57.
6. Writing Group for the Women's Health Initiative. Risks and benefits of oestrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 2002;288:321-333.
7. Anderson GL, Limacher M, Assaf AR et al. The WHI Steering Committee. Effects of conjugated equine oestrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomised controlled trial. JAMA 2004;291:1701-1712.
8. McClung MR. Prevention and management of osteoporosis. Best Pract Res Clin Endocrinol Metab 2003;17:53-72.
9. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047-1059.
10. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer: is it safe?) a randomised comparison: trial stopped. Lancet 2004;363:453-455.
11. Million Women Study Collaborators. Patterns of use of hormone replacement therapy in one million women in Britain 1996-2000. BJOG 2002;109:1319-1330.
12. Lowe G, Woodward M, Vessey M, Rutney A, Gough P, Daly E. Thrombotic variables and risk of ideopathic venous thromboembolism in women aged 45-64 years. Thromb Haemost 2000;83:530-535.
13. Scarabin P-Y, Oger E, Plu-Bureau G. Oestrogen and THromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-432.
14. Espeland MA, Rapp SR, Schumaker SA, et al. Conjugated equine oestrogens and global cognitive function in postmenopausal women. Women's Health Initiative Memory Study. JAMA 2004;291:2959-2968.
15. Lobo R. Evaluation of cardiovascular event rates with hormone therapy in healthy, early menopausal women. Arch In Med 2004;164:482-487.